← Home / Dare Bioscience, Inc. (DARE)
Stock Analysis
Dare Bioscience, Inc. (DARE)
DARE
DARE · Market data
1.33 -0.82%
Track DARE in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when DARE price is:
52W Range Position
8%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-06 19:02 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
1.75
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
17
●
Listing Compliance
HIGH
DARE listing compliance update
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
8-K Filing • SEC EDGAR
JUN
12
●
Management / Board
MEDIUM
DARE board and management update
The Meeting was held on June 11, 2026 and the following proposals were voted upon by our stockholders.
8-K Filing • SEC EDGAR
MAY
14
●
Financial Results
HIGH
DARE reports financial results
(Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S.
8-K Filing • SEC EDGAR
What's Driving DARE?
📈 Technical recovery is improving
Momentum is Neutral. Watch 1.75 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
36.0
Price Chart
DARE — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-05
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$19.6M
Company size
EV
$1.7M
Debt-adjusted value
P/E
-1.6
Not meaningful
P/S
16.3
Premium
P/B
26.7
Very high
EV/Sales
1.4
Low sales multiple
EV/EBIT
-0.1
Not meaningful
P/FCF
-1.9
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
152,455
↗ Strong
📈 Net Income
-3.00M
↘ Negative
🧮 EPS (Basic)
-0.21
↘ Negative
Dare Bioscience, Inc.
Related Opportunities